Top Insider Health Stock Purchases : INFI, AEGR, CLSN, APRI

New York, NY -- (SBWIRE) -- 05/29/2013 -- Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares climbed 5.72% to $25.69. The company, on May 15, announced that Phase 1 clinical data for IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 31 through June 4 in Chicago, Ill., and the 12th International Conference on Malignant Lymphoma (ICML), which is being held from June 19 through June 22 in Lugano, Switzerland.